Novant Health Cancer Institute is leading the charge in transforming cancer care through advanced cellular therapies that harness the body's own immune system to combat cancer.

These innovative treatments aim to not only slow disease progression, but also enhance the body's natural defenses against abnormal cell growth.

Let's dive in.

Pioneering cellular therapies at Novant Health

Among the cutting-edge treatments offered are several Chimeric Antigen Receptor T-cell (CAR-T) therapy options. This personalized approach involves modifying a patient's own T-cells to target and eliminate cancer cells, proving especially effective for recurrent or treatment-resistant lymphomas, acute lymphoblastic leukemia, and multiple myeloma.

In addition to CAR-T therapy, Novant Health offers bispecific antibody therapy. This advanced treatment is designed to recognize and bind to multiple cell markers, effectively directing the immune system to identify and destroy cancer cells.

Expanding access through clinical trials

Demonstrating a strong commitment to research and innovation, Novant Health is actively involved in clinical trials to broaden the application of cellular therapies. The institute is among the first to offer tumor-infiltrating lymphocyte (TIL) therapy for patients with refractory solid tumors, including participation in international phase two trials targeting non-small cell lung cancer.

By integrating these advanced therapies into their comprehensive cancer care, Novant Health continues to set new standards in treatment, offering hope and improved outcomes for patients across the region.

To discover more about Novant Health's innovative cancer treatments and find out if they're right for you or a loved one, visit their website.

The future of cancer treatment